{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:09:07Z","timestamp":1779224947179,"version":"3.51.4"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T00:00:00Z","timestamp":1778630400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T00:00:00Z","timestamp":1779148800000},"content-version":"vor","delay-in-days":6,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Health Qual Life Outcomes"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Bronchiectasis (BE) is a chronic lung disease that impacts health-related quality of life (HRQoL). BE has historically been separated into cystic fibrosis (CF)-related BE (CFBE) and non\u2013CF-related BE (NCFBE [where NCFBE is etiologically heterogeneous or idiopathic]), despite both sharing similar pathophysiology. Patient-reported outcome measures (PROMs) assessing BE symptoms and impacts on HRQoL have largely been developed and validated in NCFBE. This study assessed whether PROMs developed for NCFBE reflect HRQoL experiences of people with CFBE.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A preliminary conceptual model of symptoms and HRQoL impacts most relevant to people with CFBE was developed based on expert opinion, the content of existing PROMs, and previous qualitative research. Items from 11 existing PROMs were mapped to this preliminary conceptual model. A focus group discussion guide was created from the preliminary conceptual model. US participants aged\u2009\u2265\u200919 years with a self-reported diagnosis of CF and BE were eligible for participation in one of two focus groups (December 2023 or January 2024). Focus groups were recorded and transcribed verbatim, and thematic analysis (ATLAS.ti Web) was used to identify recurring themes from the discussions. Final themes were mapped back to the preliminary conceptual model to identify potential gaps between existing PROMs and relevant HRQoL impacts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 19 people with CFBE participated in the virtual focus groups. Most participants were female (63%) and non-Hispanic White (95%), ranging from 22 to 67 years of age. Focus group discussions revealed five primary themes: Emotional Symptoms, Physical Function, Physical Symptoms, Social Health, and Treatment Burden. A total of 242 unique mentions of BE-related symptoms and impacts on HRQoL were mapped to the model. Generally, concerns about symptoms and HRQoL impacts expressed by participants were consistent with the model. Potential discrepancies included feelings of loss of control, sinusitis, and hemoptysis. Although not included in the model, loss of control likely overlapped with anxiety or treatment burden. Hemoptysis, although raised during focus group discussions, was not captured in the model, but is captured in several PROMs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Measures developed to assess patient\u2011reported outcomes in NCFBE may be extended to CFBE, pending cognitive and psychometric validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12955-026-02546-4","type":"journal-article","created":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T09:37:26Z","timestamp":1778665046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Patient-reported outcome measures developed for non\u2013cystic fibrosis bronchiectasis may be applied to cystic fibrosis bronchiectasis"],"prefix":"10.1186","volume":"24","author":[{"given":"Patrick A.","family":"Flume","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert J.","family":"Nordyke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donald","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashok","family":"Jha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gina","family":"Nicholson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John Devin","family":"Peipert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,5,13]]},"reference":[{"issue":"1","key":"2546_CR1","doi-asserted-by":"publisher","first-page":"2401551","DOI":"10.1183\/13993003.01551-2024","volume":"65","author":"JD Chalmers","year":"2024","unstructured":"Chalmers JD, Shteinberg M, Mall MA, O\u2019Donnell AE, Watz H, Gupta A, et al. Cathepsin C (dipeptidyl peptidase 1) inhibition in adults with bronchiectasis: AIRLEAF(R), a Phase II randomised, double-blind, placebo-controlled, dose-finding study. Eur Respir J. 2024;65(1):2401551.","journal-title":"Eur Respir J"},{"issue":"10150","key":"2546_CR2","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1016\/S0140-6736(18)31767-7","volume":"392","author":"PA Flume","year":"2018","unstructured":"Flume PA, Chalmers JD, Olivier KN. Advances in bronchiectasis: endotyping, genetics, microbiome, and disease heterogeneity. Lancet. 2018;392(10150):880\u201390.","journal-title":"Lancet"},{"issue":"11","key":"2546_CR3","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1016\/S2213-2600(24)00176-0","volume":"12","author":"MB Long","year":"2024","unstructured":"Long MB, Chotirmall SH, Shteinberg M, Chalmers JD. Rethinking bronchiectasis as an inflammatory disease. Lancet Respir Med. 2024;12(11):901\u201314.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2546_CR4","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s12890-018-0638-0","volume":"18","author":"R Chandrasekaran","year":"2018","unstructured":"Chandrasekaran R, Mac Aogain M, Chalmers JD, Elborn SJ, Chotirmall SH. Geographic variation in the aetiology, epidemiology and microbiology of bronchiectasis. BMC Pulm Med. 2018;18(1):83.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2546_CR5","doi-asserted-by":"publisher","first-page":"1700629","DOI":"10.1183\/13993003.00629-2017","volume":"50","author":"E Polverino","year":"2017","unstructured":"Polverino E, Goeminne PC, McDonnell MJ, Aliberti S, Marshall SE, Loebinger MR, et al. European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J. 2017;50(3):1700629.","journal-title":"Eur Respir J"},{"issue":"11","key":"2546_CR6","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.3390\/ijms22115996","volume":"22","author":"M Oriano","year":"2021","unstructured":"Oriano M, Amati F, Gramegna A, De Soyza A, Mantero M, Sibila O, et al. Protease-antiprotease imbalance in bronchiectasis. Int J Mol Sci. 2021;22(11):5996.","journal-title":"Int J Mol Sci"},{"key":"2546_CR7","doi-asserted-by":"crossref","unstructured":"Polverino E, Rosales-Mayor E, Torres A. Exacerbation of Bronchiectasis. In Bronchiectasis. Edited by Chalmers JD, Polverino E, Aliberti S. Cham, Switzerland: Springer; 2018: 205\u2013222.","DOI":"10.1007\/978-3-319-61452-6_15"},{"issue":"3","key":"2546_CR8","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1183\/20734735.007516","volume":"12","author":"M Redondo","year":"2016","unstructured":"Redondo M, Keyt H, Dhar R, Chalmers JD. Global impact of bronchiectasis and cystic fibrosis. Breathe (Sheff). 2016;12(3):222\u201335.","journal-title":"Breathe (Sheff)"},{"issue":"6","key":"2546_CR9","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1016\/j.chest.2023.06.040","volume":"164","author":"JM Roberts","year":"2023","unstructured":"Roberts JM, Goyal V, Kularatna S, Chang AB, Kapur N, Chalmers JD, et al. The economic burden of bronchiectasis: A systematic review. Chest. 2023;164(6):1396\u2013421.","journal-title":"Chest"},{"issue":"7","key":"2546_CR10","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S2213-2600(23)00093-0","volume":"11","author":"JD Chalmers","year":"2023","unstructured":"Chalmers JD, Polverino E, Crichton ML, Ringshausen FC, De Soyza A, Vendrell M, et al. Bronchiectasis in Europe: data on disease characteristics from the European Bronchiectasis registry (EMBARC). Lancet Respir Med. 2023;11(7):637\u201349.","journal-title":"Lancet Respir Med"},{"issue":"1","key":"2546_CR11","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/s12890-018-0631-7","volume":"18","author":"EK Dudgeon","year":"2018","unstructured":"Dudgeon EK, Crichton M, Chalmers JD. The missing ingredient: the patient perspective of health related quality of life in bronchiectasis: a qualitative study. BMC Pulm Med. 2018;18(1):81.","journal-title":"BMC Pulm Med"},{"issue":"9","key":"2546_CR12","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.3390\/jpm13091310","volume":"13","author":"A Nicola","year":"2023","unstructured":"Nicola A, Oancea C, Barata PI, Adelina M, Mateescu T, Manolescu D, et al. Health-related quality of life and stress-related disorders in patients with bronchiectasis after pulmonary resection. J Pers Med. 2023;13(9):1310.","journal-title":"J Pers Med"},{"issue":"3","key":"2546_CR13","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1016\/j.athoracsur.2014.04.049","volume":"98","author":"CC Vallilo","year":"2014","unstructured":"Vallilo CC, Terra RM, de Albuquerque ALP, Suesada MM, Mariani AW, Salge JM, et al. Lung resection improves the quality of life of patients with symptomatic bronchiectasis. Ann Thorac Surg. 2014;98(3):1034\u201341.","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"2546_CR14","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.hrtlng.2019.09.004","volume":"49","author":"A Cakmak","year":"2020","unstructured":"Cakmak A, Inal-Ince D, Sonbahar-Ulu H, Bozdemir-Ozel C, Ozalp O, Calik-Kutukcu E, et al. Physical activity of patients with bronchiectasis compared with healthy counterparts: a cross-sectional study. Heart Lung. 2020;49(1):99\u2013104.","journal-title":"Heart Lung"},{"issue":"1","key":"2546_CR15","doi-asserted-by":"publisher","first-page":"2095104","DOI":"10.1080\/20018525.2022.2095104","volume":"9","author":"J M\u00e4ntyl\u00e4","year":"2022","unstructured":"M\u00e4ntyl\u00e4 J, Witold M, Tanja T, Paula B, Kauppi P. In bronchiectasis, poor physical capacity correlates with poor quality of life. Eur Clin Respir J. 2022;9(1):2095104.","journal-title":"Eur Clin Respir J"},{"key":"2546_CR16","doi-asserted-by":"publisher","first-page":"3005","DOI":"10.2147\/NDT.S121147","volume":"12","author":"EY \u00d6zg\u00fcn Niksarlioglu","year":"2016","unstructured":"\u00d6zg\u00fcn Niksarlioglu EY, \u00d6zkan G, G\u00fcnl\u00fco\u011flu G, Uysal MA, G\u00fcl S, Kilic L, et al. Factors related to depression and anxiety in adults with bronchiectasis. Neuropsychiatr Dis Treat. 2016;12:3005\u201310.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"173","key":"2546_CR17","doi-asserted-by":"publisher","first-page":"240001","DOI":"10.1183\/16000617.0001-2024","volume":"33","author":"MA Mall","year":"2024","unstructured":"Mall MA, Davies JC, Donaldson SH, Jain R, Chalmers JD, Shteinberg M. Neutrophil serine proteases in cystic fibrosis: role in disease pathogenesis and rationale as a therapeutic target. Eur Respir Rev. 2024;33(173):240001.","journal-title":"Eur Respir Rev"},{"issue":"1","key":"2546_CR18","doi-asserted-by":"publisher","first-page":"e000998","DOI":"10.1136\/bmjresp-2021-000998","volume":"8","author":"K Bresnick","year":"2021","unstructured":"Bresnick K, Arteaga-Solis E, Millar SJ, Laird G, LeCamus C. Burden of cystic fibrosis in children < 12 years of age prior to the introduction of CFTR modulator therapies. BMJ Open Respir Res. 2021;8(1):e000998.","journal-title":"BMJ Open Respir Res"},{"issue":"2","key":"2546_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.jcf.2015.09.008","volume":"15","author":"DR VanDevanter","year":"2016","unstructured":"VanDevanter DR, Kahle JS, O\u2019Sullivan AK, Sikirica S, Hodgkins PS. Cystic fibrosis in young children: A review of disease manifestation, progression, and response to early treatment. J Cyst Fibros. 2016;15(2):147\u201357.","journal-title":"J Cyst Fibros"},{"issue":"5","key":"2546_CR20","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/resp.13495","volume":"24","author":"JK Quint","year":"2019","unstructured":"Quint JK, Smith MP. Paediatric and adult bronchiectasis: diagnosis, disease burden and prognosis. Respirology. 2019;24(5):413\u201322.","journal-title":"Respirology"},{"key":"2546_CR21","doi-asserted-by":"publisher","first-page":"105940","DOI":"10.1016\/j.rmed.2020.105940","volume":"166","author":"JS Imam","year":"2020","unstructured":"Imam JS, Duarte AG. Non-CF bronchiectasis: orphan disease no longer. Respir Med. 2020;166:105940.","journal-title":"Respir Med"},{"issue":"14","key":"2546_CR22","doi-asserted-by":"publisher","first-page":"334","DOI":"10.21037\/atm.2019.06.62","volume":"7","author":"A Magge","year":"2019","unstructured":"Magge A, Ashraf S, Quittner AL, Metersky ML. Quality of life in patients with bronchiectasis: a 2-year longitudinal study. Ann Transl Med. 2019;7(14):334.","journal-title":"Ann Transl Med"},{"issue":"3","key":"2546_CR23","first-page":"e14231","volume":"13","author":"S Chaurasia","year":"2021","unstructured":"Chaurasia S, Haran A, Reddy A, Chawla P. Association between non-cystic fibrosis bronchiectasis and quality of life: a single-center cross-sectional study. Cureus. 2021;13(3):e14231.","journal-title":"Cureus"},{"key":"2546_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.4103\/jrms.JRMS_665_20","volume":"26","author":"R Sami","year":"2021","unstructured":"Sami R, Zohal M, Khanali F, Esmailzadehha N. Quality of life and its determinants in patients with noncystic fibrosis bronchiectasis. J Res Med Sci. 2021;26:27.","journal-title":"J Res Med Sci"},{"key":"2546_CR25","doi-asserted-by":"crossref","unstructured":"Tong A, Sainsbury P, Craig J. Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews andfocus groups. Int J Qual Health Care. 2007;19(6):349\u201357.","DOI":"10.1093\/intqhc\/mzm042"},{"issue":"5","key":"2546_CR26","doi-asserted-by":"publisher","first-page":"1601532","DOI":"10.1183\/13993003.01532-2016","volume":"49","author":"A Spinou","year":"2017","unstructured":"Spinou A, Siegert RJ, Guan WJ, Patel AS, Gosker HR, Lee KK, et al. The development and validation of the Bronchiectasis Health Questionnaire. Eur Respir J. 2017;49(5):1601532.","journal-title":"Eur Respir J"},{"issue":"5","key":"2546_CR27","doi-asserted-by":"publisher","first-page":"2003156","DOI":"10.1183\/13993003.03156-2020","volume":"57","author":"ML Crichton","year":"2021","unstructured":"Crichton ML, Dudgeon EK, Shoemark A, Chalmers JD. Validation of the Bronchiectasis Impact Measure (BIM): a novel patient-reported outcome measure. Eur Respir J. 2021;57(5):2003156.","journal-title":"Eur Respir J"},{"issue":"3","key":"2546_CR28","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1183\/09031936.00102509","volume":"34","author":"PW Jones","year":"2009","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648\u201354.","journal-title":"Eur Respir J"},{"issue":"11","key":"2546_CR29","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/j.rmed.2008.06.009","volume":"102","author":"B Crawford","year":"2008","unstructured":"Crawford B, Monz B, Hohlfeld J, Roche N, Rubin B, Magnussen H, et al. Development and validation of a cough and sputum assessment questionnaire. Respir Med. 2008;102(11):1545\u201355.","journal-title":"Respir Med"},{"issue":"4","key":"2546_CR30","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1378\/chest.128.4.2347","volume":"128","author":"AL Quittner","year":"2005","unstructured":"Quittner AL, Buu A, Messer MA, Modi AC, Watrous M. Development and validation of The Cystic Fibrosis Questionnaire in the United States: a health-related quality-of-life measure for cystic fibrosis. Chest. 2005;128(4):2347\u201354.","journal-title":"Chest"},{"issue":"7","key":"2546_CR31","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1016\/j.jaip.2020.04.048","volume":"8","author":"S Ghadersohi","year":"2020","unstructured":"Ghadersohi S, Price CPE, Jensen SE, Beaumont JL, Kern RC, Conley DB, et al. Development and preliminary validation of a new patient-reported outcome measure for chronic rhinosinusitis (CRS-PRO). J Allergy Clin Immunol Pract. 2020;8(7):2341\u201350. e2341.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"2546_CR32","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1136\/thorax.58.4.339","volume":"58","author":"SS Birring","year":"2003","unstructured":"Birring SS, Prudon B, Carr AJ, Singh SJ, Morgan MD, Pavord ID. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax. 2003;58(4):339\u201343.","journal-title":"Thorax"},{"issue":"2","key":"2546_CR33","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1378\/chest.13-1891","volume":"146","author":"AL Quittner","year":"2014","unstructured":"Quittner AL, Marciel KK, Salathe MA, O\u2019Donnell AE, Gotfried MH, Ilowite JS, et al. A preliminary quality of life questionnaire-bronchiectasis: a patient-reported outcome measure for bronchiectasis. Chest. 2014;146(2):437\u201348.","journal-title":"Chest"},{"issue":"6","key":"2546_CR34","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","volume":"145","author":"PW Jones","year":"1992","unstructured":"Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George\u2019s Respiratory Questionnaire. Am Rev Respir Dis. 1992;145(6):1321\u20137.","journal-title":"Am Rev Respir Dis"},{"issue":"3","key":"2546_CR35","doi-asserted-by":"publisher","first-page":"00712","DOI":"10.1183\/23120541.00712-2022","volume":"9","author":"VH Shih","year":"2023","unstructured":"Shih VH, Jison M, Bark E, Venerus M, Meyers O, Chalmers JD. The Bronchiectasis Exacerbation Diary: a novel patient-reported outcome for non-cystic fibrosis bronchiectasis. ERJ Open Res. 2023;9(3):00712\u20132022.","journal-title":"ERJ Open Res"},{"issue":"1","key":"2546_CR36","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12931-019-1272-y","volume":"21","author":"A Artaraz","year":"2020","unstructured":"Artaraz A, Crichton ML, Finch S, Abo-Leyah H, Goeminne P, Aliberti S, et al. Development and initial validation of the bronchiectasis exacerbation and symptom tool (BEST). Respir Res. 2020;21(1):18.","journal-title":"Respir Res"},{"key":"2546_CR37","unstructured":"Savvy Cooperative. Home page. https:\/\/www.savvy.coop \/ Accessed 20 June 2025."},{"issue":"2","key":"2546_CR38","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1191\/1478088706qp063oa","volume":"3","author":"V Braun","year":"2006","unstructured":"Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77\u2013101.","journal-title":"Qual Res Psychol"},{"key":"2546_CR39","unstructured":"Atlas.ti. Home page. https:\/\/atlasti.com\/atlas-ti-web. Accessed 20 June 2025."},{"key":"2546_CR40","unstructured":"U.S. Food & Drug Administration. Guidance for industry: patient-reported outcome measures: use in medical product development to support labeling claims. https:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM193282.pdf. Accessed 28 November 2019."},{"issue":"1","key":"2546_CR41","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41467-023-36244-2","volume":"14","author":"L Allen","year":"2023","unstructured":"Allen L, Allen L, Carr SB, Davies G, Downey D, Egan M, et al. Future therapies for cystic fibrosis. Nat Commun. 2023;14(1):693.","journal-title":"Nat Commun"},{"key":"2546_CR42","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.3389\/fphar.2019.01662","volume":"10","author":"M Lopes-Pacheco","year":"2019","unstructured":"Lopes-Pacheco M. CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol. 2019;10:1662.","journal-title":"Front Pharmacol"},{"issue":"Suppl 1","key":"2546_CR43","first-page":"S69","volume":"56","author":"SG Kapnadak","year":"2021","unstructured":"Kapnadak SG, Ramos KJ, Dellon EP. Enhancing care for individuals with advanced cystic fibrosis lung disease. Pediatr Pulmonol. 2021;56(Suppl 1):S69\u201378.","journal-title":"Pediatr Pulmonol"},{"issue":"1","key":"2546_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, Macek M, Madge S, Davies JC, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"2546_CR45","doi-asserted-by":"publisher","first-page":"104174","DOI":"10.1016\/j.lpm.2023.104174","volume":"52","author":"M Barbosa","year":"2023","unstructured":"Barbosa M, Chalmers JD. Bronchiectasis. Presse Med. 2023;52(3):104174.","journal-title":"Presse Med"},{"issue":"6","key":"2546_CR46","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1016\/j.jaip.2019.02.026","volume":"7","author":"E Handley","year":"2019","unstructured":"Handley E, Nicolson CH, Hew M, Lee AL. Prevalence and clinical implications of chronic rhinosinusitis in people with bronchiectasis: a systematic review. J Allergy Clin Immunol Pract. 2019;7(6):2004\u201312. e2001.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"2546_CR47","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.3390\/healthcare10071351","volume":"10","author":"J Ancel","year":"2022","unstructured":"Ancel J, Launois C, Perotin J-M, Ravoninjatovo B, Mulette P, Hagenburg J, et al. Health-related quality of life in adults with cystic fibrosis: familial, occupational, social, and mental health predictors. Healthcare. 2022;10(7):1351.","journal-title":"Healthcare"},{"issue":"2","key":"2546_CR48","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.jcf.2008.09.007","volume":"8","author":"GS Sawicki","year":"2009","unstructured":"Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros. 2009;8(2):91\u20136.","journal-title":"J Cyst Fibros"},{"issue":"1","key":"2546_CR49","doi-asserted-by":"publisher","first-page":"e3368","DOI":"10.1002\/brb3.3368","volume":"14","author":"E Riachi","year":"2024","unstructured":"Riachi E, Holma J, Laitila A. Psychotherapists\u2019 perspectives on loss of sense of control. Brain Behav. 2024;14(1):e3368.","journal-title":"Brain Behav"},{"issue":"1","key":"2546_CR50","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s12890-018-0630-8","volume":"18","author":"J Schafer","year":"2018","unstructured":"Schafer J, Griese M, Chandrasekaran R, Chotirmall SH, Hartl D. Pathogenesis, imaging and clinical characteristics of CF and non-CF bronchiectasis. BMC Pulm Med. 2018;18(1):79.","journal-title":"BMC Pulm Med"},{"issue":"3","key":"2546_CR51","doi-asserted-by":"publisher","first-page":"104169","DOI":"10.1016\/j.lpm.2023.104169","volume":"52","author":"I Fajac","year":"2023","unstructured":"Fajac I, Burgel PR. Cystic fibrosis. Presse Med. 2023;52(3):104169.","journal-title":"Presse Med"},{"issue":"3","key":"2546_CR52","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1513\/AnnalsATS.202302-133OC","volume":"21","author":"YH Gao","year":"2024","unstructured":"Gao YH, Zheng HZ, Lu HW, Li YY, Feng Y, Gu SY, et al. Quality-of-Life Bronchiectasis Respiratory Symptom Scale Predicts the Risk of Exacerbations in Adults with Bronchiectasis: A Prospective Observational Study. Ann Am Thorac Soc. 2024;21(3):393\u2013401.","journal-title":"Ann Am Thorac Soc"}],"container-title":["Health and Quality of Life Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12955-026-02546-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-026-02546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12955-026-02546-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T21:02:23Z","timestamp":1779224543000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12955-026-02546-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,13]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2546"],"URL":"https:\/\/doi.org\/10.1186\/s12955-026-02546-4","relation":{},"ISSN":["1477-7525"],"issn-type":[{"value":"1477-7525","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,13]]},"assertion":[{"value":"13 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was submitted to an independent US-based institutional review board (IRB) organization, Advarra, in August 2023. The IRB determined that, per 5 CFR 46.104(d)(2), this study was exempt from IRB oversight. All focus group participants signed consent forms, which detailed consent for the recording of the focus groups.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The participant consent form made focus group participants aware that the sponsor may publish anonymized results in relation to the research. All participants consented to having these results published and seen by the public.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors report support for the present manuscript from Boehringer Ingelheim. PAF reports grants\/contracts and consultancy fees from Boehringer Ingelheim and Insmed. RJN reports receiving consultancy fees from Boehringer Ingelheim, Novo Nordisk, and the National Pharmaceutical Council; and has stock ownership with Amgen. DH and AJ are employees of Boehringer Ingelheim. GN has nothing to disclose. JDP reports receiving grants or contracts from the US Food and Drug Administration and UK Research and Innovation, as well as consultancy fees from Beta6 Consulting Group, Day One Pharmaceuticals, Orphalan SA, and Veloxis Pharmaceuticals.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"74"}}